0.12 USD
▲+0.01+3.96%
盘后 0.11 +1.06%
2026-08-03
市值
$5.30M
市盈率
—
EPS
-0.39
股息率
—
52 周区间
0.10 – 6.31
成交量
4.90M
Beta
0.74
目标价
—
52W 低 0.1052W 高 6.31
价格走势
公司简介
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.